1 Thing to Know Before Betting on the Next Blockbuster Drug

The guest on this week's nationally syndicated Motley Fool Money radio show is Ron Adner, an award-winning professor and author of the new book The Wide Lens: A New Strategy for Innovation. In the past decade, major pharmaceutical companies such as Eli Lilly, Pfizer, and MannKind were in a race to be the first to market an inhalable insulin. In this audio segment, Adner details how Pfizer did everything right, only to fail on a massive scale. Adner provides shareholders of pharmaceutical companies a key insight into what those companies need if they want to succeed in creating the next blockbuster drug.

Johnson & Johnson is just one of the companies in The Motley Fool's report featuring some of the biggest and best-known brand names in global business. It's called "Secure Your Future With 11 Rock-Solid Dividend Stocks," and you can get access it to it right now at no cost. Simply click here -- it's free.

Chris Hill owns shares of Pfizer. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 25, 2012, at 12:11 PM, optionfun wrote:

    The lung function test is not even 2% of why Exubera failed. Can't believe anyone would waste money on this book.

    Difficult titration, huge device that is inconvenient and looks like a bong, more expensive, and no better pharmakokinetics than current availble insulins. Their only market was for needle phobia.

    Just a little research shows Afrezza from Mannkind is better in every way. The lung function test won't make a damn bit of difference in a few years when Afrezza is approved. Book it.

  • Report this Comment On February 28, 2012, at 9:19 AM, retiredpharma wrote:

    I must agree w/optionfun..adler is clueless about why PFE and Exubera FAILED and LFTs and Endocrine docs is BS...lets not forget that PFE is the KING of Serendipity and changing COURSE midstream and Viagra is the personification of lets not hang our hat on miscalculating the target early adopters...that was easily was the DEVICE sucks plain and simple...


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1791440, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:08:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,067.78 -94.57 -0.52%
S&P 500 2,136.35 -4.99 -0.23%
NASD 5,245.36 3.53 0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 10:52 AM
LLY $78.57 Down -0.17 -0.22%
Eli Lilly and Co. CAPS Rating: ***
MNKD $0.62 Up +0.01 +1.84%
MannKind CAPS Rating: *
NVO $41.33 Up +0.29 +0.71%
Novo Nordisk CAPS Rating: *****
PFE $32.31 Down -0.23 -0.70%
Pfizer CAPS Rating: ****
SNY $37.68 Down -0.39 -1.02%
Sanofi CAPS Rating: *****